Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc.
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Investor's Business Daily on MSN1d
Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss DrugNovo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.
Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss treatments, but the ...
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of ...
Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...
Investors including Quadria Capital and Denmark-based pharmaceutical major Novo Nordisk are among those interested in a ...
In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback